GZUHF yields 869.57% · PFE yields 6.13%● Live data
📍 GZUHF pulled ahead of the other in Year 1
Combined, GZUHF + PFE cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of GZUHF + PFE for your $10,000?
Guangzhou R&F Properties Co., Ltd., together with its subsidiaries, engages in the development and sale of residential and commercial properties in the People's Republic of China, Malaysia, Cambodia, Korea, the United Kingdom, and Australia. The company invests in and develops various properties, including hotels, office buildings, shopping malls, logistics parks, and other retail properties in Beijing, Guangzhou, and other cities; and engages in construction business. It is also involved in the operation and management of hotels and a theme park under the Hainan R&F Ocean Paradise name; provides property management and leasing, and architectural and engineering design services, as well as marketing development services; and operates a football club. In addition, the company operates offline exhibition and trading complex; and offers online ecological industry operation platform services. Further, it operates diet, healthcare, sports, and culture and entertainment centers; and a hospital that provides prevention and healthcare, health assessment and management, diagnosis, treatment, and rehabilitation services, as well as elderly care services. Additionally, the company provides planning and designing, supervision, construction, landscaping, electrical and service installation, and interior decoration services. It also engages in the design and consulting of buildings and urban planning projects; installation of electromechanical and crane equipment, fire-fighting facilities, intelligent construction, power supply, and distribution projects. As of December 31, 2021, the company operated 93 deluxe hotels. Guangzhou R&F Properties Co., Ltd. was founded in 1994 and is headquartered in Guangzhou, the People's Republic of China.
Full GZUHF Calculator →Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Full PFE Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.